Social Media Sidebar

Announcement

Please sign up, comment on articles and bring your friends!

Current poll

PlanetTech is asking:

What do you think about our new web site?

Love it, indeed
Really good solution
Same as old one
The old one was better
This is a new option

Quote of the day

We are all now connected by the Internet, like neurons in a giant brain.

 

Stephen Hawking

 

New immunotherapy cancer drug hailed as 'game changer'

RATE THIS! +58
Posted in Science on 10th Oct, 2016 01:52 AM by AlexMuller

An immunotherapy drug has been described as a potential "game-changer" with promising early results presented at the European Cancer Congress. In a study of head and neck cancer, more patients taking th new drug nivolumab survived for longer compared with those who were treated with chemotherapy.

 

In another study, combining nivolumab with another drug shrank tumours in advanced kidney cancer patients.

 

Immunotherapy works by harnessing the immune system to destroy cancer cells. Advanced head and neck cancer has very poor survival rates. In a trial of more than 350 patients, published in the New England Journal of Medicine, 36% treated with the immunotherapy drug nivolumab were alive after one year compared with 17% who received chemotherapy.
 
Patients also experienced fewer side effects from immunotherapy. The benefits were more pronounced in patients whose tumours had tested positive for HPV (human papillomavirus). These patients survived an average of 9.1 months with nivolumab and 4.4 months with chemotherapy.
 
Normally, this group of patients are expected to live less than six months. Early data from a study of 94 patients with advanced kidney cancer showed that the double hit of nivolumab and ipilimumab resulted in a significant reduction in the size of tumours in 40% of patients.
 
Of these patients, one in 10 had no sign of cancer remaining. This compares with 5% of patients showing tumour reduction after standard therapy. About 12,000 people are diagnosed with kidney cancer in the UK each year and an average of 12 people die from the disease each day.
 
"I feel a bit of a fraud having terminal cancer because I haven't been in pain at all," says Peter Waite, 64, from Hertfordshire. "There's been nothing negative about it for me and I feel a bit embarrassed really."
 
Peter started receiving combined immunotherapy (nivolumab and ipilimumab) in a clinical trial in early 2015 after doctors discovered he had a type of renal cancer several years after recovering from kidney and lung cancer.
 
He was told he probably had three to five years left. Instead of being treated with chemotherapy, he spent four months receiving both immunotherapy drugs and experienced virtually no side effects, allowing him to continue working as a motor technician throughout his treatment.
 
Scans of his kidney and lungs show that one of his tumours has shrunk and two others have not shown any further growth. He is no longer taking the drugs and is being monitored every 12 weeks with scans.
 
"I feel very privileged to have had the opportunity to go on the trial."
 
As yet, nivolumab has only been approved for treating skin cancer and in June it became one of the fastest medicines ever approved for NHS use, in combination with ipilimumab, for the same cancer.
 
Nivolumab and ipilimumab both work by interrupting the chemical signals that cancers use to convince the immune system they are healthy tissue.
 
Prof Kevin Harrington of the Institute of Cancer Research and consultant at the Royal Marsden Hospital in London, who led the head and neck cancer trial, said nivolumab could be a real "game changer" for patients with advanced head and neck cancer.
 
"This trial found that it can greatly extend life among a group of patients who have no existing treatment options, without worsening quality of life.
 
"Once it has relapsed or spread, head and neck cancer is extremely difficult to treat. So it's great news that these results indicate we now have a new treatment that can significantly extend life, and I'm keen to see it enter the clinic as soon as possible."
 
Prof Paul Workman, chief executive of The Institute of Cancer Research, said nivolumab was one of a new wave of immunotherapies that were beginning to have an impact across cancer treatment.
 
He added: "We hope regulators can work with the manufacturer to avoid delays in getting this drug to patients who have no effective treatment options left to them."

Tags: bloodcancerimmunotherapyhealthmedicinedrugresearchoncology

Read original article » Back to category

Comments

Author: Guest
Posted: 2016-10-10
+1
New drug, new hope! There are many advances in cancer treatments and recently immunotherapy was considered as one that is going to have the biggest impact, promising Reply


 

Recent headlines

  • Posted in Business on 2017-04-29 13:25:52
    Google Is Becoming 'A.I. First'..read more
    Posted in Science on 2017-04-29 13:18:48
    SpaceX looks to break into national security launch.....read more
    Posted in Medicine on 2017-04-29 13:07:03
    China Is Racing Ahead in the Quest to Cure Cancer With.....read more
    Posted in Science on 2017-04-28 18:56:10
    Martian Soil Could Be Used to Build a Colony..read more
    Posted in Business on 2017-04-28 18:45:58
    President Trump’s Tax Plan Would Give Alphabet $47B..read more
Posted in Business on 2013-10-10 01:33
China is working towards a manned lunar mission in about.....read more
Posted in Business on 2013-10-20 07:17
Spacex says China is their main competitor for commercial.....read more
Posted in Software on 2013-10-20 06:43
Pirate Bay Browser Clocks 1,000,000 Downloads..read more
Posted in Medicine on 2013-10-10 02:10
Google reportedly investing hundreds of millions into new.....read more
Posted in Medicine on 2013-10-14 03:13
Endothelial Cells Can Repair and Regenerate Organs,.....read more
Posted in Science on 01.01.2010
Spacex says China is their main competitor for commercial.....read more
Posted in Science on 01.01.2010
Staring at Your Phone Could Be Making You Short Sighted..read more
Posted in Science on 01.01.2010
Oculus Rift virtual reality headset coming to mobile, but.....read more
Posted in Science on 01.01.2010
China is working towards a manned lunar mission in about.....read more
Posted in Science on 01.01.2010
Delivering drugs via nanoparticles to target mitochondria..read more

Recent Blog Posts

  • Posted by AlexMuller
    Nanoparticle vaccine shows potential as immunotherapy to fight.....read more
    Posted by AlexMuller
    Obesity is top cause of preventable life-years lost, study shows..read more
    Posted by AlexMuller
    Light can be utilized to control gene function..read more
    Posted by AlexMuller
    Brain stimulation restores memory during lapses, research shows..read more
    Posted by AlexMuller
    Wax worm caterpillar will eat plastic shopping bags: New.....read more

Login to your Account

Login to your PlanetTech Account here

Username:
Password:
Remember me
or

Create a New Account

You just need username and password

The following errors occured:
Username:
Email:
Password:
Verify password:
Remember me